Market Overview:
The global cytokine inhibitor market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of autoimmune diseases, rising geriatric population, and technological advancements in cytokine inhibitors. However, the high cost of treatment is a major restraint for the growth of this market. The global cytokine inhibitor market is segmented on the basis of type, application, and region. On the basis of type, it is divided into etanercept, infliximab, adalimumab golimumab certolizumab pegol). Etanercept dominates this market owing to its high efficacy and safety profile as compared to other drugs in its class. In terms of application; medical care accounts for majority share in this market followed by research & development and others segments respectively .
Product Definition:
Cytokine inhibitors are substances that block cytokines, proteins that coordinate and control the body's immune response. Cytokine inhibitors are important for treating diseases in which the overproduction of cytokines plays a role, such as rheumatoid arthritis and psoriasis. They can also be used to prevent transplant rejection.
Etanercept:
Etanercept is a recombinant human interleukin inhibitor. It works by decreasing the production of cytokines, which are protein inflammatory molecules that act in the immune system to stimulate and amplify an immune response. Etanercept has been approved by the U.
Infliximab:
Infliximab is a human monoclonal antibody that was developed by the pharmaceutical company, Merck & Co. It was approved by the U.S. FDA for treatment of relapsing forms of multiple sclerosis in July 2003 and for Crohn's disease in March 2006 as well as for psoriasis in April 2007.
Application Insights:
Medical care was the largest application segment in 2017 and is expected to continue its dominance over the forecast period. The growing usage of cytokine inhibitors for treatment of various diseases, such as rheumatoid arthritis, Crohn¢â‚¬â„¢s disease, psoriasis, and multiple sclerosis is anticipated to drive the market growth. In addition, increasing R&D activities pertaining to development of new drugs targeting cytokine receptors is further estimated to augment industry size by 2030.
The experiment application segment held a substantial share in 2017 due largely to extensive R&D initiatives undertaken by major pharmaceutical companies for development of novel drugs targeting different types of cytokines with different mechanisms of action.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and rising incidence of rheumatoid arthritis are some factors responsible for its large share. In addition, increasing government initiatives to raise awareness regarding diagnosis and treatment of autoimmune diseases is expected to propel the demand for cytokine inhibitors in this region. For instance, Health Canada has approved a Cytokine Inhibitor Education Program (CIEP) that provides information about inflammatory disorders such as rheumatoid arthritis and psoriasis as well as other conditions such as cancer or HIV infection & AIDS through interactive online modules along with patient handouts that can be downloaded at no cost from their website.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to an increase in healthcare expenditure by governments coupled with rising prevalence of chronic diseases like cancer & diabetes which require long term treatment courses leading to high adoption rates for biologics products including cytokine inhibitors.
Growth Factors:
- Increasing incidence of autoimmune diseases: The increasing incidence of autoimmune diseases is one of the key growth drivers for the cytokine inhibitor market. Cytokines are known to play a role in the development and progression of autoimmune diseases, which is expected to drive demand for cytokine inhibitors in the coming years.
- Growing awareness about cytokine inhibitors: There is growing awareness about cytokine inhibitors among healthcare professionals and patients alike, which is expected to drive demand for these drugs in the coming years.
- Technological advancements: The advent of novel technologies such as monoclonal antibodies has led to significant advances in the field of cytokine inhibition, thereby driving growth prospects for this market.
- Rising prevalence of cancer: Cancer is one major indication where cytokines have been implicated in tumorigenesis and progression, thus propelling demand for effective therapies such as cytokine inhibitors. This trend is likely to continue in future, resulting in robust growth prospects for this market over the forecast period . 5) Emerging markets offer lucrative opportunities: The emerging markets offer a lucrative opportunity owing to their large population base and growing economies
Scope Of The Report
Report Attributes
Report Details
Report Title
Cytokine Inhibitor Market Research Report
By Type
Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab pegol
By Application
Medical Care, Experiment, Others
By Companies
Celgene, Merck, Novartis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
167
Number of Tables & Figures
117
Customization Available
Yes, the report can be customized as per your need.
Global Cytokine Inhibitor Market Report Segments:
The global Cytokine Inhibitor market is segmented on the basis of:
Types
Etanercept, Infliximab, Adalimumab, Golimumab, Certolizumab pegol
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Medical Care, Experiment, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Celgene
- Merck
- Novartis
Highlights of The Cytokine Inhibitor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Etanercept
- Infliximab
- Adalimumab
- Golimumab
- Certolizumab pegol
- By Application:
- Medical Care
- Experiment
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Cytokine Inhibitor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
A cytokine inhibitor is a medication that blocks the action of cytokines, proteins that help regulate the immune system. Cytokine inhibitors can be used to treat a variety of conditions, including cancer and autoimmune diseases.
Some of the key players operating in the cytokine inhibitor market are Celgene, Merck, Novartis.
The cytokine inhibitor market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Cytokine Inhibitor Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Cytokine Inhibitor Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Cytokine Inhibitor Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Cytokine Inhibitor Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Cytokine Inhibitor Market Size & Forecast, 2018-2028
4.5.1 Cytokine Inhibitor Market Size and Y-o-Y Growth
4.5.2 Cytokine Inhibitor Market Absolute $ Opportunity
Chapter 5 Global Cytokine Inhibitor Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Cytokine Inhibitor Market Size Forecast by Type
5.2.1 Etanercept
5.2.2 Infliximab
5.2.3 Adalimumab
5.2.4 Golimumab
5.2.5 Certolizumab pegol
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Cytokine Inhibitor Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Cytokine Inhibitor Market Size Forecast by Applications
6.2.1 Medical Care
6.2.2 Experiment
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Cytokine Inhibitor Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Cytokine Inhibitor Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Cytokine Inhibitor Analysis and Forecast
9.1 Introduction
9.2 North America Cytokine Inhibitor Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Cytokine Inhibitor Market Size Forecast by Type
9.6.1 Etanercept
9.6.2 Infliximab
9.6.3 Adalimumab
9.6.4 Golimumab
9.6.5 Certolizumab pegol
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Cytokine Inhibitor Market Size Forecast by Applications
9.10.1 Medical Care
9.10.2 Experiment
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Cytokine Inhibitor Analysis and Forecast
10.1 Introduction
10.2 Europe Cytokine Inhibitor Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Cytokine Inhibitor Market Size Forecast by Type
10.6.1 Etanercept
10.6.2 Infliximab
10.6.3 Adalimumab
10.6.4 Golimumab
10.6.5 Certolizumab pegol
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Cytokine Inhibitor Market Size Forecast by Applications
10.10.1 Medical Care
10.10.2 Experiment
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Cytokine Inhibitor Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Cytokine Inhibitor Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Cytokine Inhibitor Market Size Forecast by Type
11.6.1 Etanercept
11.6.2 Infliximab
11.6.3 Adalimumab
11.6.4 Golimumab
11.6.5 Certolizumab pegol
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Cytokine Inhibitor Market Size Forecast by Applications
11.10.1 Medical Care
11.10.2 Experiment
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Cytokine Inhibitor Analysis and Forecast
12.1 Introduction
12.2 Latin America Cytokine Inhibitor Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Cytokine Inhibitor Market Size Forecast by Type
12.6.1 Etanercept
12.6.2 Infliximab
12.6.3 Adalimumab
12.6.4 Golimumab
12.6.5 Certolizumab pegol
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Cytokine Inhibitor Market Size Forecast by Applications
12.10.1 Medical Care
12.10.2 Experiment
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Cytokine Inhibitor Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Cytokine Inhibitor Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Cytokine Inhibitor Market Size Forecast by Type
13.6.1 Etanercept
13.6.2 Infliximab
13.6.3 Adalimumab
13.6.4 Golimumab
13.6.5 Certolizumab pegol
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Cytokine Inhibitor Market Size Forecast by Applications
13.10.1 Medical Care
13.10.2 Experiment
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Cytokine Inhibitor Market: Competitive Dashboard
14.2 Global Cytokine Inhibitor Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Celgene
14.3.2 Merck
14.3.3 Novartis
